PIK3CB and neoplasm: Therapeutic strategies targeting the PI3K pathway, owing to the core role of PI3K signaling in numerous tumor pathogenic processes, are rapidly evolving and entering preclinical and early clinical trials (Beck et al., 2014; Alzahrani, 2019; Tewari et al., 2022; Yu et al., 2022).